Overdose Risk Management and Naloxone

ClinicalTrials.gov ID: NCT03933345

Public ClinicalTrials.gov record NCT03933345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Overdose Risk Management and Compensation in the Era of Naloxone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A growing body of research underscores the life- and cost-saving advantages of equipping people who use opioids with naloxone, but very little is known about: 1) barriers to naloxone awareness and access, and 2) the potential psychosocial and behavioral impacts of being "protected" by naloxone while engaging in overdose risk behaviors, of using naloxone on someone else, and of surviving an overdose in which naloxone is used. This research will provide insight into both of these domains to yield a richly contextualized understanding of the processes and mechanisms underlying changes in overdose risk behaviors related to naloxone access and use and will illuminate the disparities that may limit access to naloxone for some or result in compensatory behavior following naloxone exposure for others. Findings from this study will provide an empirical basis to strengthen and refine existing overdose prevention efforts and to design tailored interventions to engage opioid users who have recently survived or reversed an overdose.

Study identification

NCT ID: NCT03933345
Recruitment status: Not listed
Study type: Observational
Phase: Not listed
Lead sponsor: National Development and Research Institutes, Inc.; Other
Enrollment: 600 participants

Conditions and interventions

Conditions

Opioid Use

Interventions

Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control. Other

Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 4, 2019
Primary completion: Jul 31, 2022
Completion: Aug 30, 2023
Last update posted: Apr 30, 2019

2019 – 2023

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
270 West 25th Street	New York	New York	10001	Recruiting
National Development and Research Institutes, Inc.	New York	New York	10010	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03933345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2019 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03933345 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →